The Persistent Promise of Combining HGF/MET and EGFR Inhibition in Non-Small Cell Lung Cancer

Cancer - United States
doi 10.1002/cncr.30718
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Triple Inhibition of EGFR, Met, and VEGF Suppresses Regrowth of HGF-Triggered, Erlotinib-Resistant Lung Cancer Harboring an EGFR Mutation

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2014English

Effects of AKT Inhibition on HGF-mediated Erlotinib Resistance in Non-Small Cell Lung Cancer Cell Lines

Journal of Cancer Research and Clinical Oncology
MedicineCancer ResearchOncology
2014English

Dual Inhibition of EGFR and mTOR Pathways in Small Cell Lung Cancer

British Journal of Cancer
Cancer ResearchOncology
2010English

Combining Chemotherapy With Epidermal Growth Factor Receptor Inhibition in Advanced Non-Small Cell Lung Cancer

Therapeutic Advances in Medical Oncology
Oncology
2012English

Cryobiopsy Increases the EGFR Detection Rate in Non-Small Cell Lung Cancer

Lung Cancer
Cancer ResearchOncologyRespiratory MedicinePulmonary
2020English

EGFR Mutations Status for Non-Small-Cell Lung Cancer Patients

Sveikatos mokslai
2016English

OA14 Phase 2 Study: Tepotinib + Gefitinib in MET+/Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

154P: Plasma Dynamic Monitoring of Soluble C-Met Level for EGFR-TKI Treatment in Advanced Non-Small Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2016English

MiR-206 Inhibits HGF-induced Epithelial-Mesenchymal Transition and Angiogenesis in Non-Small Cell Lung Cancer via C-Met /PI3k/ Akt/mTOR Pathway

Oncotarget
Oncology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy